Monaco Asset Management SAM Buys Shares of 25,000 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Monaco Asset Management SAM bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 25,000 shares of the company’s stock, valued at approximately $146,000.

Other large investors have also recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $62,000. SG Americas Securities LLC grew its stake in shares of Olema Pharmaceuticals by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock worth $102,000 after purchasing an additional 4,419 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Olema Pharmaceuticals by 867.6% in the 4th quarter. AlphaQuest LLC now owns 18,414 shares of the company’s stock worth $107,000 after purchasing an additional 16,511 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $111,000. Finally, Conway Capital Management Inc. acquired a new position in shares of Olema Pharmaceuticals in the 3rd quarter worth approximately $119,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $4.37 on Friday. The firm’s 50 day simple moving average is $5.25 and its 200-day simple moving average is $8.66. The company has a market cap of $250.39 million, a P/E ratio of -2.00 and a beta of 2.11. Olema Pharmaceuticals, Inc. has a fifty-two week low of $3.95 and a fifty-two week high of $16.62.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Tuesday.

Insider Transactions at Olema Pharmaceuticals

In other news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were acquired at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. The trade was a 4.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director G. Walmsley Graham sold 700,761 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total transaction of $4,730,136.75. The disclosure for this sale can be found here. 19.40% of the stock is currently owned by insiders.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.